- Home
- AIM
as 11-15-2024 4:00pm EST
AIM ImmunoTech Inc is an immuno-pharma company focused on research and development of therapeutics to treat immune disorders and viral and cancer diseases. AIM's flagship products include Ampligen (Rintatolimod), a drug of large macromolecular RNA molecules for cancer and viral diseases, and the drug Alferon N Injection for a category of STD infection. Clinical trials of Ampligen include studies of cancer patients with renal cell carcinoma, malignant melanoma, colorectal cancer, advanced recurrent ovarian cancer, and triple-negative metastatic breast cancer. It is also advancing Ampligen as a potential treatment for COVID-19. FDA has authorized the first human trial assessing the safety and effectiveness of Ampligen in combination with interferon alfa-2b, in cancer patients with COVID-19.
| Founded: | 1966 | Country: | United States |
| Employees: | N/A | City: | OCALA |
| Market Cap: | 15.9M | IPO Year: | N/A |
| Target Price: | $3.00 | AVG Volume (30 days): | 295.4K |
| Analyst Decision: | Strong Buy | Number of Analysts: | 2 |
| Dividend Yield: | N/A | Dividend Payout Frequency: | N/A |
| EPS: | -0.46 | EPS Growth: | N/A |
| 52 Week Low/High: | $0.21 - $0.62 | Next Earning Date: | 11-15-2024 |
| Revenue: | $190,000 | Revenue Growth: | -1.55% |
| Revenue Growth (this year): | -25% | Revenue Growth (next year): | 1086.80% |
Stock Insider Trading Activity of AIM ImmunoTech Inc. (AIM)
| Name | Ticker | Relationship | Date | Transaction | AVG Cost Per Share | Shares | Total Value | Securities Owned After Transaction(s) | SEC Form 4 |
|---|---|---|---|---|---|---|---|---|---|
| Equels Thomas K | AIM | CEO & President | Sep 16 '24 | Buy | $0.30 | 5,000 | $1,515.00 | 1,493,042 | |
| Equels Thomas K | AIM | CEO & President | Sep 13 '24 | Buy | $0.31 | 20,000 | $6,160.00 | 1,493,042 |
Latest AIM ImmunoTech Inc. News
AIM Breaking Stock News: Dive into AIM Ticker-Specific Updates for Smart Investing
GuruFocus.com
2 days ago
AIM ImmunoTech Inc (AIM) Q3 2024 Earnings Call Highlights: Strategic Advances Amid Financial ...
GlobeNewswire
3 days ago
AIM ImmunoTech Reports Third Quarter 2024 Financial Results and Provides Corporate Update
GlobeNewswire
11 days ago
AIM ImmunoTech to Discuss Third Quarter 2024 Financial Results on November 15, 2024 and Host Conference Call and Webcast
Business Wire
14 days ago
AIM ImmunoTech Files Definitive Proxy Statement and Sends Letter to Shareholders
GlobeNewswire
a month ago
AIM ImmunoTech to Participate in the 2024 Healthcare Virtual Summit, Presented by Maxim Group LLC
GlobeNewswire
a month ago
AIM ImmunoTech Granted U.S. Patent for Ampligen® for the Treatment of Endometriosis
GlobeNewswire
2 months ago
AIM ImmunoTech Announces Pricing of $1.26 Million Registered Direct Offering
GlobeNewswire
2 months ago
AIM ImmunoTech to Participate in Virtual Investor CEO Connect Segment
Compare AIM vs Leading Stocks
Share on Social Networks:
Disclaimer
The information presented on this page, "AIM AIM ImmunoTech Inc. - Stocks Price | History | Analysis", including historical data, forecasts, news, insider information, and predictions, is provided for educational purposes only. It should not be considered as financial advice or a recommendation to buy or sell any securities. Decisions regarding investments should be made only after careful consideration and consultation with a qualified financial advisor. We do not endorse or guarantee the accuracy or reliability of the information provided, and we disclaim any liability for financial losses incurred as a result of decisions made based on the information presented.